Sullivan and Skadden get it on for $1bn takeover of 'female Viagra' maker
US firms called in as Valeant agrees to buy Sprout after its libido enhancing drug gained regulatory approval this week
August 21, 2015 at 05:20 AM
2 minute read
Sullivan & Cromwell and Skadden Arps Slate Meagher & Flom have won roles advising as Canada's Valeant agrees to buy Sprout Pharmaceuticals for $1bn (£640m).
Valeant made an offer after Sprout gained regulatory approval this week (19 August) for its libido-enhancing drug. Flibanserin, marketed as Addyi, has been dubbed the "female Viagra".
Sullivan & Cromwell is advising Sprout on the deal with a New York-based team including corporate partners Matthew Hurd, Stephen Kotran, tax partner Ronald Creamer and executive compensation & benefits partner Matthew Friestedt.
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2How I Made Office Managing Partner: 'If You Are Aware of Areas for Improvement and You Can Play a Role in That, Speak Up,' Says Jennifer Mellott of Freshfields
- 3'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5Burns & Levinson to Wind Down After 64 Years in Boston
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250